BioPharmSignal logoBioPharmSignal

Company Profile

Bluejay Diagnostics Stock Price, News & Catalysts

Ticker:
BJDX
Exchange:
NASDAQ
Sector:
MedTech
Location:
United States

Stock performance

1.02 USD (-2.86%)

Close

Last updated: August 17, 2026

4.49M USD

Market cap

Why the stock is moving

As of Aug 17, 2026, BJDX closed down 2.86% at $1.02. No new same-company headline was identified in the current news window.

Company overview

Critical-Care Diagnostics

Bluejay Diagnostics develops rapid blood tests for hospital and critical-care settings using its Symphony diagnostic platform.

Symphony Platform

Symphony is an automated, near-patient testing system designed to provide quantitative biomarker results without relying on a central laboratory workflow.

Symphony IL-6 Test

The lead test measures interleukin-6 as an aid in assessing critically ill patients. The SYMON-II pivotal study enrolled hospitalized patients to support analytical and clinical validation.

U.S. Manufacturing Strategy

Bluejay is establishing domestic manufacturing and supply-chain capacity in preparation for regulatory submission and potential commercialization.

Future catalysts

  • Planned FDA 510(k) submission for the Symphony IL-6 test following completion of analytical and clinical validation.

Recent news

  1. 01

    Bluejay Diagnostics Reports Q2 2026 Results; Strengthened Balance Sheet Supports Advancement of Symphonyâ„¢ IL-6 Toward Regulatory Submission and Commercialization

  2. 02

    Bluejay Diagnostics Announces Successful Completion of Enrollment in the SYMON-II Multicenter Clinical Validation Study

  3. 03

    Bluejay Diagnostics Announces Closing of Up to $23.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

  4. 04

    Bluejay Diagnostics Announces up to $23.6 Million Private Placement Priced At-the-Market Under Nasdaq Rules

  5. 05

    Bluejay Diagnostics and Argonaut Manufacturing Services Announce Strategic Partnership

Similar stocks

Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.

TTOO

T2 Biosystems

PRPO

Precipio Diagnostics

ICU

SeaStar Medical

AEMD

Aethlon Medical

TLIS

Talis Biomedical Corp

VRAX

Virax Biolabs

CRMD

CorMedix Inc.

GERN

Geron

Frequently Asked Questions

What is the current stock price of Bluejay Diagnostics (BJDX)?

Bluejay Diagnostics (BJDX) most recently closed at 1.02 USD, a -2.86% move versus the previous session.

What is the market cap of Bluejay Diagnostics (BJDX)?

Bluejay Diagnostics currently has a market capitalization of 4.49M USD on BioPharmSignal.

What does Bluejay Diagnostics do?

Critical-Care Diagnostics Bluejay Diagnostics develops rapid blood tests for hospital and critical-care settings using its Symphony diagnostic platform. Symphony Platform Symphony is an automated, near-patient testing system designed to provide quantitative biomarker results without relying on a central laboratory workflow. Symphony IL-6 Test The lead test...

On which exchange is BJDX stock listed?

Bluejay Diagnostics (BJDX) is associated with NASDAQ, United States, MedTech.

What is IL-6?

Planned FDA 510(k) submission for the Symphony IL-6 test following completion of analytical and clinical validation.

Which conditions is Bluejay Diagnostics targeting with IL-6?

Planned FDA 510(k) submission for the Symphony IL-6 test following completion of analytical and clinical validation.

How does Bluejay Diagnostics describe recent progress with IL-6?

Planned FDA 510(k) submission for the Symphony IL-6 test following completion of analytical and clinical validation.

What is SYMON-II?

The SYMON-II pivotal study enrolled hospitalized patients to support analytical and clinical validation.